Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2006

View Archived Issues

sanofi-aventis recaps active quarter

Enrollment completed in first phase III trial of PRX-00023 in GAD

Pro-Pharmaceuticals and Mount Sinai join forces on liver fibrosis research

Case Western to study rEV-576 for myasthenia gravis

TB Alliance receives funding to advance tuberculosis drugs

Chimerix acquires lead compound library from U. of Michigan

Harvard Medical School signs macular degeneration agreement with Merck

Mechanistic evaluation of vasodilatory effects of PRX-08066

ELB-526: selective PDE4 inhibitor demonstrating antineutrophilia and safety

Dendreon presents immunotherapy targeting tumor-specific CA9

ASM-002 exhibits antiinflammatory and bronchodilatory properties

Ceptyr selects IND-enabling studies for type 2 diabetes compound

Isotechnika licenses ISA-247 to Lux for ophthalmic indications

Significant ADHD symptom control with shorter Daytrana wear time

Phosphagenics reports positive preclinical results for transdermal insulin

Elite begins second clinical study for ELI-154

BioLineRx licenses BL-3010 from Gevys for acute and chronic pain

AT-3022 fentanyl citrate transdermal patch begins U.S. phase I trials

NF-kappaB decoy oligodeoxynucleotide shown to be safe in phase I study

Translational Research developing intranasal granisetron

Dacogen now available for MDS

Zetia approved for use in combination with fenofibrate

Recent patents describe new analgesic agents

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Recent patents cover therapeutic agents for neurological disorders

Novel cathepsin S inhibitor developed by Boehringer Ingelheim shows efficacy in vivo

Inhibition of glycosylation by a disaccharide derivative prevents tumor metastasis

Schering AG presents new in vitro and in vivo data on its antitumor agent ZK-304709

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...